LEADER 03564nam  2200769Ia 450 
001 9910825936903321
005 20200520144314.0
010   $a9786612684906
010   $a9781282684904
010   $a1282684906
010   $a9780470574898
010   $a0470574895
010   $a9780470574881
010   $a0470574887
035   $a(CKB)2550000000006396
035   $a(EBL)479843
035   $a(OCoLC)501316330
035   $a(SSID)ssj0000359643
035   $a(PQKBManifestationID)11259450
035   $a(PQKBTitleCode)TC0000359643
035   $a(PQKBWorkID)10307265
035   $a(PQKB)10087662
035   $a(MiAaPQ)EBC479843
035   $a(Au-PeEL)EBL479843
035   $a(CaPaEBR)ebr10360988
035   $a(CaONFJC)MIL268490
035   $a(PPN)243321155
035   $a(OCoLC)435728364
035   $a(FINmELB)ELB178839
035   $a(Perlego)2759471
035   $a(EXLCZ)992550000000006396
100   $a20090827d2010      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aEvaluation of drug candidates for preclinical development $epharmacokinetics, metabolism, pharmaceutics, and toxicology /$fedited by Chao Han, Charles B. Davis, Binghe Wang
205   $a1st ed.
210   $aHoboken, NJ $cJohn Wiley & Sons$dc2010
215   $a1 online resource (303 p.)
225 1 $aWiley series in drug discovery and development
300   $aIncludes index.
311 08$a9780470044919 
311 08$a0470044918 
327   $aEVALUATION OF DRUG CANDIDATES FOR PRECLINICAL DEVELOPMENT; CONTENTS; PREFACE; CONTRIBUTORS; 1. INTRODUCTION; 2. PHARMACOKINETICS IN PRECLINICAL DRUG DEVELOPMENT: AN OVERVIEW; 3. THE ROLE OF MEMBRANE TRANSPORTERS IN DRUG DISPOSITION; 4. CYTOCHROME P450: STRUCTURE, FUNCTION, AND APPLICATION IN DRUG DISCOVERY AND DEVELOPMENT; 5. THE ROLE OF DRUG METABOLISM AND METABOLITE IDENTIFICATION IN DRUG DISCOVERY; 6. PROTEIN BINDING IN DRUG DISCOVERY AND DEVELOPMENT; 7. PREDICTION OF THE PHARMACOKINETICS IN HUMANS; 8. PHARMACEUTICS DEVELOPABILITY ASSESSMENT; 9. SAFETY ASSESSMENT IN DRUG DISCOVERY
327   $a10. ASSESSMENT OF STRATEGIES UTILIZED TO MINIMIZE THE POTENTIAL FOR INDUCTION OF ACQUIRED LONG QT SYNDROME AND TORSADE DE POINTESINDEX
330   $a Emphasizes the integration of major areas of drug discovery and their importance in candidate evaluation  It is believed that selecting the ""right"" drug candidate for development is the key to success. In the last decade, pharmaceutical R&D departments have integrated pharmacokinetics and drug metabolism, pharmaceutics, and toxicology into early drug discovery to improve the assessment of potential drug compounds. Now, Evaluation of Drug Candidates for Preclinical Development provides a complete view and understanding of why absorption-distribution-metabolism-excretion-toxicology (AD
410  0$aWiley series in drug discovery and development.
606   $aDrug development
606   $aPharmacokinetics
606   $aDrugs$xMetabolism
615  0$aDrug development.
615  0$aPharmacokinetics.
615  0$aDrugs$xMetabolism.
676   $a615.19
676   $a615/.19
701   $aHan$b Chao$01712234
701   $aDavis$b Charles B$g(Charles Baldwin)$0150958
701   $aWang$b Binghe$cPhD.$0915404
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910825936903321
996   $aEvaluation of drug candidates for preclinical development$94104193
997   $aUNINA